Inhibrx Biosciences, INC S-1 registration statements
Registration statements, filed ahead of a public offering, with the business description and financials a first-time investor sees.
NASDAQ
Inhibrx Biosciences registers for the resale of up to 2.4 million shares of its common stock following the completion of the INBRX-101 sale to Sanofi.